Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs CRNX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CRNX Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

CRNX Overall Winner 6-Pillar Tally: IONS 3 – 3 CRNX Matrix Metrics: IONS 4 – 6 CRNX

As of Nov 16, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas CRNX carries 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. -58.8% operating margin) and revenue trajectory (+2336.3% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile CRNX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 89.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs CRNX
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
CRNX NASDAQ Head-to-Head Winner
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
$84.95
+0.13% 1D
Market Cap $9.0B
TTM Revenue $42M
Forward P/E N/M
Beta / 30D Vol 0.29β · 2% Vol
Unified Composite Score
46.8 / 100 HOLD
Tech 45.0 Fund 48.0 Flow 60.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (36.0% over 20 days), RSI 90
RSI-14: 89.6 · SMA20: $84.53 · SMA50: $74.83

6-Pillar Scorecard Institutional Category Breakdown (IONS 3 – 3 CRNX)

Columns: Metric · IONS · CRNX
1. Valuation Multiples IONS
Forward P/E 90.9x N/M
Trailing P/E 90.9x N/M
PEG Ratio N/M N/M
EV / Revenue 6.2x N/M
2. Growth & Scale CRNX
Revenue Growth (YoY) +54.9% +2336.3%
Earnings Growth (YoY) -43.7% +0.0%
TTM Revenue (USD) $960M $42M
Market Cap $4.7B $9.0B
3. Profitability & Quality IONS
Gross Margin 3.0% N/A
Operating Margin -58.8% -527.4%
Net Profit Margin -56.9% 0.0%
Return on Equity (ROE) -108.0% -42.4%
4. Balance Sheet & Cash Flow CRNX
Cash Generation (TTM) -$623M -$425M
Cash Flow Margin -64.9% N/A
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $8.3M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CRNX
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 59.9% (17th %ile) 0.5% (<1st %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 0.07x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (4) vs CRNX (6)
Institutional Metric IONS CRNX Criterion Row Edge
Market Capitalization
Scale
$4.7B $9.0B Larger Scale CRNX
Trailing P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Forward P/E Ratio
Valuation
90.9x N/M Lower Multiple IONS
Revenue Growth (YoY)
Growth
+54.9% +2336.3% Higher Growth CRNX
Operating Margin (TTM)
Profitability
-58.8% -527.4% Higher Margin IONS
Net Profit Margin
Profitability
-56.9% 0.0% Higher Margin CRNX
Return on Equity (ROE)
Capital Efficiency
-108.0% -42.4% Higher ROE CRNX
52-Week Range Position
Momentum
2% ($27–$87) 100% ($30–$85) Stronger Trend CRNX
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.29β · 2% Vol Lower Realized Risk CRNX
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 46.8 / 100 (HOLD) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $42M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) -$425M ($8.3M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IONS +14.88 pp
IONS: +16.59% · CRNX: +1.71%
3M Horizon CRNX +166.02 pp
IONS: -19.93% · CRNX: +146.09%
6M Horizon CRNX +135.17 pp
IONS: -26.35% · CRNX: +108.82%
1Y Horizon CRNX +118.61 pp
IONS: -13.57% · CRNX: +105.04%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue CRNX Revenue IONS Op. Margin CRNX Op. Margin Margin Leader
FY2018 $600M $0M -10.2% -1182.5% IONS
FY2019 $1.12B $0M 32.6% -4512.3% IONS
FY2020 $730M $0M -23.6% -105567.6% IONS
FY2021 $810M N/A -3.7% N/A IONS
FY2022 $590M N/A -69.8% N/A IONS
FY2023 $790M $0M -44.9% -5547.2% IONS
FY2024 $710M $0M -67.4% -32613.5% IONS
FY2025 $940M $10M -40.4% -6714.8% IONS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CRNX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.5%
IV Percentile <1st %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact CRNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
CRNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.0B market capitalization and -527.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs CRNX Key Questions & Quantitative Answers

As of Nov 16, 2026, Crinetics Pharmaceuticals, Inc. (CRNX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow, Options & Positioning). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas CRNX carries 46.8/100 (HOLD) at $84.95 (N/M Forward P/E, -527.4% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. CRNX 46.8/100 HOLD), CRNX captures the overall institutional head-to-head verdict (6–4 matrix metrics and 3–3 across the 6 pillars) due to superior fundamental profitability (-527.4% vs. -58.8% operating margin) and revenue trajectory (+2336.3% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile CRNX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 89.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CRNX leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with CRNX at +2336.3% YoY revenue growth and +0.0% YoY earnings growth on $42M TTM revenue (N/A gross margin, -527.4% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while CRNX shifted N/A. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CRNX.

IONS screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas CRNX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus CRNX (-42.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, CRNX carries 0.5% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.29β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.